Tag archive for ‘KBIO’
KaloBios: The Fascinating Story of the Takeover of the Company by Martin Shkreli and His Hedge Fund Buddies (KBIO, $18.25, I would not touch this stock)
Investment Thesis and Overview KaloBios (KBIO) announced on November 13 that it was ceasing operations and had engaged a restructuring firm to help liquidate its assets. Management said they were unable to find a strategic partner interested in licensing or acquiring its technology and the Company had only around $5 million of cash. The stock […]
The BIO CEO Conference: Highlights from the Meeting and New Investment Perspectives (Subscribers Only)
Back From BIO CEO Conference I have returned from spending two days at the BIO CEO conference at the Waldorf Astoria in New York City. Through attending presentations or one on one meetings, I heard presentations from Advanced Cell Technology ACTC), Advaxis (ADXS), Agenus (AGEN), Alexion (ALXN) , Alkermes (ALKM), Aradigm (ARDM), Athersys (ATHX), Celator […]